CSCs exhibit several mechanisms that contribute to their treatment resistance. They often have enhanced DNA repair capabilities, active drug efflux pumps, and a quiescent state that makes them less susceptible to treatments targeting dividing cells. Additionally, CSCs can reside in protective niches within the tumor microenvironment, providing further resistance to therapy.
